Yes, things are looking good here. If the market holds together (big if) this stock could be high $20s soon as comparable companies are trading at 5x forward revs. I've struggled to understand the ceo change a while back, but my best guess is that Drachman wanted to sell the company and the board didn't, given the long term potential. I think the brought in Carrel to grow it and he's doing a great job. The office they just opened in Minneapolis is a clue that he plans to be here for a while. With the growth of current products and the upside of the DEEP trial, I think this could be a $3bn+ company in 5 years.
Sentiment: Strong Buy
bbrutus08, You had to like the 1st Qtr. results as well as the company guidance going forward. Did you get a chance to listen to the investors conference that is on Atricure's website? Very exciting! Also, did you notice the volume today? Looks like we are going to finally see a significant drop in the Short positions. We should see a rise for the rest of the year. $25-$27 by year's end.
This guy sounds like our old friend, J0hn_chambers under a new alias. I have been a bit puzzled by the growing short position. I can't imagine what the thesis could be other than all small cap med device cos are overvalued. Anyone who thinks this isn't worth much because it isn't profitable has no idea how to value growth equity.
Sentiment: Strong Buy
How has that "Easy" short position been doing for you this year? And you might want to reconsider Additional Shorting of this Stock, as your cohorts are heading in the other direction! Check out the volume today, Short Covering Gone Wild!!!!!!!
Do you have any clue of what you say? Tell us something that actually makes sense! Do you actually know anything at all about this company or are you just another blind short about to be taught a valuable lesson?
So this money losing company loses one cent less than the so-called experts predict and the share price is the seventh best performer of the day so far. Up 15%, just imagine what would happen if they actually made money. This is almost as easy as shorting fraudulent Chinese companies (I know, fraudulent and Chinese are synonyms).
Fair enough. Their P/S ratio is in line with the industry and gross margins did go down a little.
However the have pretty good size growth runway, approved products, and trials underway. I can't image their not being a target ripe for acquisition.
I think a reasonable pps would be for it to trade in the 22-25 range.
Cos they bought much of the growth. If you look at the 2015 guidance it is some 10% organic growth in sales over last few quarters, but costs higher and maybe gross margin bit lower, too. CEO is good talker and Board has some clout, so market cap already high? ... can it be more than a 5xsales business...
....yet the price per share languishes around the same range.
Although management is doing a good job with AtriCure, they hardly are maximizing shareholder value. Time to explore other options.